Lenabasum

Research use only, not for human use.

A synthetic nonpsychoactive cannabinoid acid with potent analgesic and anti-inflammatory activity in vivo, binds directly and selectively to PPARγ.

A synthetic nonpsychoactive cannabinoid acid with potent analgesic and anti-inflammatory activity in vivo, binds directly and selectively to PPARγ; produces significant antitumor activity and effects its actions primarily via CB(2) receptors; inhibits interleukin-8 promoter activity in a PPARgamma-dependent manner; significantly suppresses CYP-induced urinary frequency in rats at 10 mg/kg.Fibrosis Phase 2 Clinical.

IP 751 (CT-3; Ajulemic acid) is a synthetic analogue of a metabolite of Δ9-tetrahydrocannabinol, acts as a cannabinoid receptor agonist, with Kis of 5.7 nM, 56.1 nM and EC50s of 11.6 nM, 13.4 nM for hCB1 and hCB2 receptors, respectively, and has anti-inflammatory property.

IP 751 (0.1-1 mg/kg, p.o.) causes reversal of hyperalgesia in a dose-dependent manner, with a maximal reversal of 63%, ED50 value of 0.5 mg/kg in a model of neuropathic pain in the rat, and a maximal reversal of 57%, ED50 value of 0.7 mg/kg in a model of inflammatory pain in the rat. However, IP 751 (1, 3, 10 mg/kg, p.o.) shows less potent in the tetrad tests than in the chronic pain models, with ED50s of 5.3 mg/kg, 2.3 mg/kg and 4.3 mg/kg in the rotarod, catalepsy and tail-flick assays, respectively.

Ajulemic acid | IP-751 | Anabasum

Metabolic Enzyme/Protease

PPAR

PPAR

Other Indications

Fibrosis

137945-48-3

400.559

C25H36O4

>98% (HPLC)

——

CCCCCCC(C)(C)C(C=C1OC(C)2C)=CC(O)=C1[C@]3(CC(C(O)=O)=CC[C@]23[H])[H]

(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-9-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years